JP4602298B2 - 医薬製剤 - Google Patents
医薬製剤 Download PDFInfo
- Publication number
- JP4602298B2 JP4602298B2 JP2006235153A JP2006235153A JP4602298B2 JP 4602298 B2 JP4602298 B2 JP 4602298B2 JP 2006235153 A JP2006235153 A JP 2006235153A JP 2006235153 A JP2006235153 A JP 2006235153A JP 4602298 B2 JP4602298 B2 JP 4602298B2
- Authority
- JP
- Japan
- Prior art keywords
- nfκb
- nfκb decoy
- decoy
- nanoparticle
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Description
[G]nGGRHTYYHC (配列番号1)
(式中、nは0または1を、RはAまたはGを、YはCまたはTを、HはA、CまたはTをそれぞれ意味する。)
[G]nGGRHTYYHC(配列番号1)
(式中、nは0または1を、RはAまたはGを、YはCまたはTを、HはA、CまたはTをそれぞれ意味する。)
具体的には、例えばGGGATTTCCC(配列番号2)、GGGACTTTCC(配列番号3)またはGGACTTTCC(配列番号4)等が挙げられるが、これらに限定されるものではない。
「分子細胞生物学辞典」(東京化学同人 1997年発行)891頁
[NFκBデコイ含有PLGAナノスフェアの調製法]
[NFκBデコイ含有PLGAナノスフェアからのNFκBデコイ溶出試験(in vitro)]
実施例1〜4、比較例1〜3において調製したPLGAナノスフェアを用い、感作物質としてオバルブミン(卵白アルブミン、以下OVAと略す)を用いたOVA誘発遅延型アレルギー(DTH)モデルに対する抑制効果を調査した。試験方法を以下に説明する。
実施例1及び2で得られたPLGAナノスフェアを所定量秤量して少量の精製水に分散し、製剤中の水分含量が30%となるように白色ワセリンと混合して、NFκBデコイ含有率が0.05%、0.15%、0.5%の3種類のPLGAナノスフェア含有クリーム剤を調製した。また、比較対照として、NFκBデコイ2%含有ワセリン軟膏(陽性対照)及びNFκBデコイ未添加のワセリン軟膏(陰性対照)を調製した。
評価方法としては、2次感作の前日に評価サンプルを投与し、2次感作における感作物質に対する生体内の免疫システム緩和効果、即ち一旦生成した抗体によるアレルギー反応抑制効果を評価することが多いが、ここでは1次感作の前日に評価サンプルを投与することにより、アレルギー反応のさらに前段となる、受容細胞がOVAを抗原と認識しないようにする作用について評価した。
2 ポリビニルアルコール
3 カチオン性高分子
4 NFκBデコイ
Claims (12)
- 表面がキトサンまたはキトサン誘導体で被覆され、当該表面にNFκBデコイオリゴヌクレオチドが静電的に吸着担持され、かつNFκBデコイオリゴヌクレオチドが内部にも封入されている乳酸・グリコール酸共重合体のナノ粒子を含む医薬製剤。
- 前記ナノ粒子を結合剤により複合化するとともに、前記結合剤で形成された外層にNFκBデコイオリゴヌクレオチドをさらに封入したことを特徴とする請求項1に記載の医薬製剤。
- 前記NFκBデコイオリゴヌクレオチドが、以下の配列番号1で表されるNFκB結合配列を含む請求項1又は請求項2に記載の医薬製剤。
[G]nGGRHTYYHC (配列番号1)
(式中、nは0または1を、RはAまたはGを、YはCまたはTを、HはA、CまたはTをそれぞれ意味する。) - 前記NFκBデコイオリゴヌクレオチドが、NFκB結合配列としてGGGATTTCCC(配列番号2)、GGGACTTTCC(配列番号3)、又はGGACTTTCC(配列番号4)の少なくとも一つを含む請求項3に記載の医薬製剤。
- 前記NFκBデコイオリゴヌクレオチドが、配列5′−CCTTGAAGGGATTTCCCTCC−3′(配列番号5)及びこれに相補的な配列5′−GGAGGGAAATCCCTTCAAGG−3′(配列番号6)からなる二本鎖オリゴヌクレオチドである請求項4に記載の医薬製剤。
- 前記ナノ粒子表面が正のゼータ電位を有することを特徴とする請求項1乃至請求項5のいずれか1項に記載の医薬製剤。
- 前記ナノ粒子表面が+27mV以上のゼータ電位を有することを特徴とする請求項6に記載の医薬製剤。
- 前記ナノ粒子中のNFκBデコイオリゴヌクレオチドの含有率が3.5重量%以上であることを特徴とする請求項1乃至請求項5のいずれか1項に記載の医薬製剤。
- 前記ナノ粒子表面が正のゼータ電位を有し、前記ナノ粒子中のNFκBデコイオリゴヌクレオチドの含有率が3.5重量%以上30重量%以下であることを特徴とする請求項1乃至請求項5のいずれか1項に記載の医薬製剤。
- 前記ナノ粒子表面が+27mV以上のゼータ電位を有し、前記ナノ粒子中のNFκBデコイオリゴヌクレオチドの含有率が3.5重量%以上30重量%以下であることを特徴とする請求項9に記載の医薬製剤。
- 皮膚疾患の治療に使用されることを特徴とする請求項1乃至請求項10のいずれか1項に記載の医薬製剤。
- 皮膚疾患がアトピー性皮膚炎である請求項11に記載の医薬製剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006235153A JP4602298B2 (ja) | 2006-08-31 | 2006-08-31 | 医薬製剤 |
US11/812,459 US7897751B2 (en) | 2006-08-31 | 2007-06-19 | Pharmaceutical preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006235153A JP4602298B2 (ja) | 2006-08-31 | 2006-08-31 | 医薬製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008056611A JP2008056611A (ja) | 2008-03-13 |
JP4602298B2 true JP4602298B2 (ja) | 2010-12-22 |
Family
ID=39239784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006235153A Active JP4602298B2 (ja) | 2006-08-31 | 2006-08-31 | 医薬製剤 |
Country Status (2)
Country | Link |
---|---|
US (1) | US7897751B2 (ja) |
JP (1) | JP4602298B2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100132486A (ko) * | 2008-03-12 | 2010-12-17 | 안게스 엠지 인코포레이티드 | 약제 용출형 카테터 및 그 제조방법 |
US20110092438A1 (en) * | 2008-03-28 | 2011-04-21 | Angesmg, Inc. | Composition for external application comprising transcription factor decoy as active ingredient |
JP2010030923A (ja) * | 2008-07-28 | 2010-02-12 | Hosokawa Micron Corp | 薬物含有ナノ粒子及び薬物含有複合粒子、並びにそれらの製造方法 |
US8231093B2 (en) * | 2009-03-06 | 2012-07-31 | Phillip Tran | Bracket for curtain rods and the like |
JP2014001166A (ja) * | 2012-06-19 | 2014-01-09 | Sanei Gen Ffi Inc | 抗菌剤 |
JP5992247B2 (ja) * | 2012-08-13 | 2016-09-14 | 国立大学法人大阪大学 | 核酸医薬経口製剤 |
KR101601035B1 (ko) * | 2013-02-28 | 2016-03-08 | 주식회사 종근당 | 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물 |
WO2017172769A1 (en) * | 2016-03-28 | 2017-10-05 | The Johns Hopkins University | Biomimetic anisotropic polymeric particles with naturally derived cell membranes for enhanced drug delivery |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005306877A (ja) * | 2001-02-20 | 2005-11-04 | Anges Mg Inc | デコイを含む薬学的組成物およびその使用方法 |
JP2006028041A (ja) * | 2004-07-13 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | 核酸含有ナノ粒子 |
JP2006089475A (ja) * | 2004-08-27 | 2006-04-06 | Anges Mg Inc | 核酸皮膚外用製剤 |
JP3778357B2 (ja) * | 2001-02-20 | 2006-05-24 | アンジェスMg株式会社 | デコイを含む薬学的組成物およびその使用方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
EP0824918B1 (en) * | 1995-05-12 | 2007-03-28 | AnGes MG, Inc. | REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB |
DE19729769A1 (de) | 1997-07-11 | 1999-01-14 | Cardiogene Gentherapeutische S | Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie |
AU2002358947A1 (en) | 2001-12-05 | 2003-06-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof |
US20060241066A1 (en) | 2002-05-29 | 2006-10-26 | Tetsuya Tomita | Decoy composition for treating and preventing inflammatory disease |
US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
JP2006111591A (ja) | 2004-10-15 | 2006-04-27 | Anges Mg Inc | 核酸医薬を標的特異的に細胞内送達するための製剤 |
US8480647B2 (en) | 2007-05-14 | 2013-07-09 | Bioprotect Ltd. | Delivery device for delivering bioactive agents to internal tissue in a body |
-
2006
- 2006-08-31 JP JP2006235153A patent/JP4602298B2/ja active Active
-
2007
- 2007-06-19 US US11/812,459 patent/US7897751B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005306877A (ja) * | 2001-02-20 | 2005-11-04 | Anges Mg Inc | デコイを含む薬学的組成物およびその使用方法 |
JP3778357B2 (ja) * | 2001-02-20 | 2006-05-24 | アンジェスMg株式会社 | デコイを含む薬学的組成物およびその使用方法 |
JP2006028041A (ja) * | 2004-07-13 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | 核酸含有ナノ粒子 |
JP2006089475A (ja) * | 2004-08-27 | 2006-04-06 | Anges Mg Inc | 核酸皮膚外用製剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2008056611A (ja) | 2008-03-13 |
US20090061007A1 (en) | 2009-03-05 |
US7897751B2 (en) | 2011-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4602298B2 (ja) | 医薬製剤 | |
Kumar et al. | Advanced drug delivery systems for transdermal delivery of non-steroidal anti-inflammatory drugs: a review | |
Majumder et al. | Nanocarrier-based systems for targeted and site specific therapeutic delivery | |
Erdoğar et al. | Nanocapsules for drug delivery: an updated review of the last decade | |
JP5457414B2 (ja) | オリゴヌクレオチド含有マイクロスフェア、1型糖尿病を処置する医薬の製造のための、その使用 | |
Lin et al. | Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era | |
US10322089B2 (en) | Nanoparticles, nanoparticle delivery methods, and systems of delivery | |
Tsai et al. | Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations | |
Tahara et al. | Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery | |
US9415019B2 (en) | Nanocapsules with a polymer shell | |
Cui et al. | Nanodelivery systems for topical management of skin disorders | |
CN109069527B (zh) | 纳米颗粒、控释剂型和用于递送免疫治疗剂的方法 | |
Özbaş-Turan et al. | Topical application of antisense oligonucleotide-loaded chitosan nanoparticles to rats | |
Gupta et al. | Use of nanotechnology in antimicrobial therapy | |
JP2007099631A (ja) | アニオン性薬物封入ナノ粒子の製造方法及びそれを用いた医薬製剤 | |
Yadav et al. | Polymers in topical delivery of anti-psoriatic medications and other topical agents in overcoming the barriers of conventional treatment strategies | |
Aldawsari et al. | Progress in topical siRNA delivery approaches for skin disorders | |
EP2422776A1 (en) | Polyarginine nanocapsules | |
Zhai et al. | Nanomedicines for the treatment of glaucoma: current status and future perspectives | |
Li et al. | Size-transformable gelatin/nanochitosan/doxorubicin nanoparticles with sequentially triggered drug release for anticancer therapy | |
US8647661B1 (en) | Surface modified multilayered nanostructures for dermal delivery | |
Peng et al. | Gout therapeutics and drug delivery | |
Pourmadadi et al. | Recent advancements in the targeted delivery of Gemcitabine: Harnessing Nanomedicine for Enhanced Cancer Therapy | |
Barbosa et al. | Nanotechnology applied in drug delivery | |
Singh et al. | Lipid nanoparticulate drug delivery systems: approaches toward improvement in therapeutic efficacy of bioactive molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090625 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090722 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20100526 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20100617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100902 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100928 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100929 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131008 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4602298 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D03 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |